Therapeutic Action
Antiretroviral, HIV-1 non nucleoside reverse transcriptase inhibitor
PDF page 127
Drug reference
Antiretroviral, HIV-1 non nucleoside reverse transcriptase inhibitor
PDF page 127
HIV-1 infection, in combination with other antiretrovirals
PDF page 127
Do not administer to children under 3 years and to patients with severe hepatic impairment. Do not combine with amodiaquine (risk of hepatotoxicity). Administer with caution to patients with psychiatric disorders (or history of) or epilepsy. Administer with caution and monitor combination with: central nervous system depressants (opioids, benzodiazepines, phenobarbital, etc.), carbamazepine, phenytoin, oral anticoagulants; QT prolonging drugs (amiodarone, co-artemether, mefloquine, quinine, haloperidol, etc.). May cause: neuropsychiatric disorders: dizziness, headache, insomnia, drowsiness, abnormal dreaming, anxiety, aggressive behaviour, impaired concentration, seizures, depression, suicidal ideation; hepatotoxicity and gastrointestinal disturbances; skin reactions, possibly severe (Stevens-Johnson syndrome). Efavirenz reduces the efficacy of implants and oral contraceptives: use injectable medroxyprogesterone or an intrauterine device. Pregnancy: no contra-indication
PDF page 128
200 mg breakable tablet, 200 mg capsule and 600 mg tablet
PDF page 127
The daily dose is administered once daily at bedtime, on an empty stomach. Child 3 years and over and adult: Weight Daily dose Tablets or capsules 1 tab 200 mg 10 to < 14 kg 200 mg or 1 cap 200 mg 14 to < 25 kg 300 mg 1 tab 200 mg + ½ tab 200 mg 2 tab 200 mg 25 to < 35 kg 400 mg or 2 cap 200 mg 2 tab 200 mg 400 mg ≥ 35 kg or 2 cap 200 mg or 600 mg or 1 tab 600 mg Duration Depending on the efficacy and tolerance of efavirenz.
PDF page 127
Capsules can be opened and their content mixed into a spoon with a small amount of food. Also comes in fixed-dose combinations (tenofovir/emtricitabine/efavirenz or tenofovir/lamivudine/efavirenz). Preferably use these formulations when available.
PDF page 128
– – Below 25 °C
PDF page 128